Abstracts variances. RESULTS: Data were available for 1669 employees with FD and a control group of (274,206) employees without FD. The FD group's costs (per employee/year) were twice as high ($3676) summed across all direct medical and work absence measures (P < 0.0001). The individual differences (favoring FD) in medical and pharmacy costs were $3420 and $365, respectively (both P < 0.0001). Work absence costs had differences of $103 (SL, P < 0.0001), $104 (STD, P = 0.0370), $7 (LTD, P = 0.6551). Measured units of productivity were 2 units less/hour with the FD group (P = 0.055). CONCLUSION: This study confirms earlier work from Sweden, but shows that in the US, FD can be costly to employers. Physicians and patients need more education on the ROME II criteria and how to integrate this information into improving medical and pharmaceutical costs. The risk of gastrointestinal ulcers is enhanced by non-steroidal anti-inflammatory drugs (NSAID). Proton pump inhibitors (PPI) are used for gastroprotection, but their effectiveness has been documented only in few studies (Hooper et al. BMJ 2004; 329:948-57). We therefore investigated in the gastroprotective effects of PPI on diclofenac-induced ulcer risk. METHODS: A nested case control study was performed based on claims data from a large German sickness fund. A cohort was constructed consisting of all beneficiaries enrolled in the health plan continuously from 2000 until 2004. Cases had an inpatient treatment due to peptic ulcer starting at or after January 1st 2003 with the case onset being the index date. All other beneficiaries were randomly allocated to an index date, and ten controls per case were drawn. For the 90 days before the index date it was checked, if diclofenac and/or PPI were dispensed. The influence of diclofenac alone as well as with concomitant PPI prescription on ulcer risk was analysed using logistic regression models. RESULTS: We identified 979 cases and 10,319 controls in the cohort of 752,613 beneficiaries. The stratified analysis according to the prescription of diclofenac alone or in combination with PPI showed that diclofenac prescriptions within the 90 days before the index day increased the risk for hospitalization due to peptic ulcer significantly (odds ratio (OR) 3.21; 95%CI 2.59-3.96; p < 0.001). The risk was reduced (OR 1.26; 95%CI 0.68-2.30; p = 0.46), if PPI were prescribed concomitantly with diclofenac. The significance of the PPI effect was demonstrated by inserting an interaction term in a regression model without stratification, where a risk reduction of 63% (OR 0.37; 95%CI 0.18-0.74; p = 0.005) was found. CONCLUSION: The concomitant prescription of PPI and diclofenac decreases the hospitalization risk due to peptic ulcer thus supporting the use of PPI as gastroprotective agents. To conduct an economic evaluation of terlipressin and octreotide used in the UK in the treatment of Bleeding Oesophageal Varices (BOV). METHODS: Efficacy results from Cochrane meta-analyses were used. Baseline course of disease and health-related utility (HRU) were retrieved from published sources. Hospitalization related data were extracted from HODaR, a large longitudinal database. Costs were obtained from published sources, BNF and HODaR. A discrete event simulation model was coded in VBA with the following transition states: bleeding, no bleeding, no bleeding post-TIPS, post-salvage surgery, and death. Weibull curves were fitted to estimate baseline survival, re-bleeding rates, and failure to control bleeding. Simulations were run for up to five years since initial bleeding. Prices were in UK£2005 and a discount rate of 3.5% was applied to costs and benefits. Sensitivity analysis was run with C++ dll engine. RESULTS: Terlipressin was found to be cost-effective with baseline values of ICER at 1 year £5263/QALY (£3865/LYG) versus octreotide and £5618/QALY (£4136/LYG) versus placebo. In baseline analysis octreotide was not cost-effective against placebo. Based on deterministic and probabilistic sensitivity analyses terlipressin remained cost-effective when compared to octreotide and placebo; it was cost-saving for some of the varied input values. Distribution of ICER values demonstrated cost-effectiveness of octreotide versus placebo, but on CEAC curve, probability of cost-effectiveness of octreotide and placebo were of the same magnitude: 24.0% and 23.4%, respectively, at £20,000/QALY. The results were sensitive to utility variables, but were generally robust and independent of assumptions regarding baseline risk. Total Expected Value of Perfect Information at 1 year varied from £928 to £220 per patient depending on the range of variation of input variables. CONCLUSIONS: Terlipressin is cost-effective when compared to octreotide and placebo for the treatment of BOV in cirrhotic patients. Further analysis is needed to establish cost-effectiveness of octreotide versus placebo.
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GI3 COST-UTILITY ANALYSIS IN A UK SETTING OF VASOACTIVE DRUG TREATMENTS IN ACUTE BLEEDING OESOPHAGEAL VARICES IN CIRRHOTIC PATIENTS-A DISCRETE EVENT

GI4 COST-EFFECTIVENESS OF TRIPLE THERAPIES OF ESOMEPRAZOLE AND RABEPRAZOLE FOR H. PYLORI ERADICATION IN THE PUBLIC SECTOR OF HONG KONG
Lee KK, Lee VWY, Chan FK The Chinese University of Hong Kong, Shatin, Hong Kong, China OBJECTIVES: To assess the cost-effectiveness of two commonly used triple therapies for H. pylori eradication in a public hospital in Hong Kong. METHODS: A prospective observational design was adopted. Two cohorts of patients attending the GI Specialty Clinic at the Prince of Wales Hospital with endoscopically confirmed non-ulcer dyspepsia and H. pylori positive confirmed by CLO Test were recruited. Informed consent from patients and ethic approval from hospital were obtained. The patients were consecutively recruited to receive esomeprazole + amoxicillin + clarithromycin (EAC) or rabeprazole + amoxicillin + clarithromycin (RAC) therapies. One-week treatment was given and urea breath test was performed after 4 weeks to confirm if eradication was successful. Initial treatment failures were given quadruple rescue therapy (metronidazole + esomeprazole + danol + tetracycline). All health care resources including clinic visits, laboratory procedures, medications, and professional services were recorded. RESULTS: One-hundred and three and 96 patients were recruited to the EAC and RAC groups respectively. The demographic characteristics were not significantly different except the RAC group had a lower rate of drinking and smoking habits. The success rates for eradication for the EAC and RAC groups were 88.5% and 85.4% respectively (p = NS). The cost/successful eradication for EAC group and RAC group was USD846 and USD843.7 respectively. The cost/successful eradication after quadruple therapy was USD871 and
